RDD Blog

R&D Directions Insider

Meet Our Editors

Asia shifting toward stratified medicine

March 14, 2013 – 9:58 am by Chris

Asia is the worldâ€™s growth engine, and is building its reputation as a hub for current and future healthcare R&D activities. Â There is an unprecedented growth in global health care R&D activities in the region with numerous multinational pharmaceutical corporations and contract research organizations moving their operations to Asia. Stratified medicine, also known as personalized [...]

Tags: Asia, Bayer, biology, biopharmaceutical companies, cardiovascular disease, chronic disease, clinical biomarkers, contract research organizations, diabetes, electronic medical records, genome analysis market, healthcare, infectious diseases, lung disease, mental health diseases, oncology, personalized medicines, pharmaceutical companies, R&D, science, scientists, stratified medicine, technology

Posted in Uncategorized | No Comments »

Acquisition creates new CRO, SynteractHCR

March 14, 2013 – 9:37 am by Chris

By Mia Burns
Synteract has now completed its acquisition of Harrison Clinical Research and will now be known as the new multination contract research organization SynteractHCR. The corporate headquarters are in San Diego County. Wendel Barr is the CEO for SynteractHCR. Dr. Francisco Harrison, formerly HCRâ€™s chairman and founder, will remain a senior member of [...]

Tags: clinical studies, contract research organization, data management services, electronic data capture, harrison clinical research, medidata, oncology, solution, Synteract

Posted in Uncategorized | No Comments »

IDEA Pharma backs transparency at AllTrials.net

March 11, 2013 – 8:01 am by Chris

IDEA Pharma is the first pharmaceutical consultancy to support the â€œAll Trials Registered, All Results Reportedâ€ campaign at AllTrials.net. IDEA insists that the pharma industry may only thrive with more transparency. Associate Web Editor Mia Burns interviewed Mike Rea, CEO of IDEA Pharma.
Q: How did IDEA become the first pharma consultancy to support the [...]

Tags: clinical trial data, clinicians, data collection, drug launches, GlaxoSmithKline, medicines, patient confidentiality, pharma industry, pharmaceutical consultancy, prescribing, product launches, published data, real world data, transparency

Posted in Uncategorized | No Comments »

Novartis partnership in Zambia tackles rheumatic heart disease

March 4, 2013 – 9:11 am by Chris

By Mia Burns
Novartis announced last week an effort to eradicate rheumatic heart disease in Zambia through a collaboration with Lusaka University Teaching Hospital, the Ministry of Health in Zambia, the Pan-African Cardiology Society, and Massachusetts General Hospital.
Rheumatic heart disease is a complication of untreated streptococcal infections in which the valves of the heart are scarred [...]

Tags: anitbiotics, clinical trials, drug discovery, Novartis, pencillin, penicillin, pharmaceutical companies, research and development, rheumatic heart disease

Posted in Uncategorized | No Comments »

Covance and Royal Liverpool and Broadgreen University Hospitals NHS Trust Partner for Early Stage Research

February 25, 2013 – 2:04 pm by Chris

Covance and the Royal Liverpool and Broadgreen University Hospitals NHS Trust announced in January an exclusive five-year agreement to work together in conducting early stage clinical trials at the Royal Liverpool University Hospital. The Trust plans to complete its expansion by 2017 which will help establish the Royal Liverpool University Hospital and the region as [...]

Tags: biotech, contract research organizations, Covance, pharmaceutical

Posted in Uncategorized | No Comments »

Quintiles Files for IPO a Second Time

February 19, 2013 – 12:40 pm by Chris

By Mia Burns
Contract research organization Quintiles announced on Friday its filing of registration statements with the U.S. Securities and Exchange Commission, making it the companyâ€™s second IPO. The CRO has gone back and forth between being private and public for years, starting in the mid-1990s. Quintilesâ€™ initial IPO was in 1994, but then the [...]

Tags: contract research organization, initial public offering, Quintiles, SEC, shareholders, shares

Posted in Uncategorized | No Comments »

Lilly Oncology Maintains its PACE with Cancer Perception Index

February 11, 2013 – 5:08 pm by Chris

Although the public is generally satisfied with the progress in cancer research that has occurred during the last two decades, people still believe that it takes too long for new cancer drugs to reach patients and that their countries fail to invest enough in fighting cancer. Many are concerned that the current economic crisis will [...]

Tags: Eli Lilly, oncology

Posted in Uncategorized | No Comments »

Lagging U.S. math, science skills forcing scientist recruiters overseas

February 4, 2013 – 1:02 pm by Chris

By Mia Burns
Many reports have surfaced that show that students in the United States have fallen behind in math and science, when compared with children in other nations. But how does this tie in with job recruitment in the life sciences? In many cases, recruiters are finding that they need to lookÂ abroad to find scientists [...]

Tags: education, healthcare agencies, life sciences, math, science

Posted in Uncategorized | No Comments »

Acurian Answers Call of Customer Demand by Doubling Consumer Marketing Group Size

February 4, 2013 – 12:50 pm by Chris

Global patient enrollment and retention solution provider Acurian has doubled its consumer marketing group to meet the demands for trial participants. Acurian is facing record levels of customer request, and an all-time high in project backlog. Associate Web Editor Mia Burns spoke to Roger Smith, senior VP of Operations at Acurian.
Q: How do you [...]

Tags: clinical trial enrollment, clinical trials, clinical trials recruitment, solution

Posted in Uncategorized | No Comments »

‘Breakthrough’ startups reap investments from new early-stage fund

January 25, 2012 – 11:33 am by Michael Christel

Cambridge, Mass.-based Flagship Ventures recently closed the company’s largest fund to date, raising $270 million for its life sciences funds, money that will add around 20 new biotechnology companies to Flagship’s portfolio, according to officials. Noubar Afeyan, Ph.D., managing partner and CEO of Flagship, answered questions from R&D Directions about the company’s latest cash infusion. [...]

Tags: biotechnology, early-stage venture capital

Posted in Uncategorized, drug discovery | No Comments »

©2013 UBM Canon